烟酰胺在高眼压大鼠模型中防止视网膜血管丢失并支持青光眼患者眼部血供
该前瞻性对照临床试验结合动物与人类组织病理学,评估烟酰胺对青光眼视网膜血管的调节作用。高眼压大鼠经烟酰胺治疗后视网膜血管参数及血管壁完整性改善;青光眼患者(n=90)与健康对照(n=30)经OCTA评估显示视网膜灌注密度小幅增加。
要点
- 烟酰胺改善高眼压大鼠视网膜血管面积、覆盖率、总长度、连接数及连接密度(均P<0.05)。
- 烟酰胺改善高眼压大鼠VE-钙黏蛋白抗体染色的血管壁完整性(P<0.01)。
- 烟酰胺治疗后健康对照视盘和黄斑完整图像灌注密度分别增加0.7%(P=0.04)和1.0%(P=0.002),青光眼患者黄斑颞侧象限增加0.7%(P=0.02)。
核心结论
- 烟酰胺可在青光眼动物模型中防止视网膜血管损伤。
- 烟酰胺治疗后,青光眼患者和健康对照经OCTA评估的视网膜血管参数小幅增加。
研究设计与样本
- 前瞻性对照临床试验,研究对象包括正常血压大鼠和高眼压大鼠、死后人眼组织、青光眼患者(n=90)和健康对照(n=30)。
- 研究采用组织病理学、计算机辅助视网膜血管分析、光学相干断层扫描血管成像(OCTA)及烟酰胺治疗。
主要发现
- 与健康对照相比,高眼压/青光眼模型中多种血管参数发生改变。
- 烟酰胺治疗改善高眼压大鼠视网膜血管,AngioTool评估的平均血管面积、血管覆盖百分比面积、总血管长度、总连接数及连接密度均增加(均P<0.05)。
- 烟酰胺治疗改善高眼压大鼠VE-钙黏蛋白抗体染色的血管壁完整性(P<0.01)。
- OCTA评估显示,烟酰胺治疗后健康对照视盘灌注密度增加0.7%(P=0.04)、黄斑完整图像灌注密度增加1.0%(P=0.002),青光眼患者黄斑颞侧象限灌注密度增加0.7%(P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether nicotinamide (NAM) modulates retinal vasculature in glaucoma. METHODS: This was a prospective controlled clinical trial investigating animal and human histopathology. Participants included normotensive and ocular hypertensive rats, postmortem human ocular tissue, glaucoma patients (n = 90), and healthy controls (n = 30). The study utilized histopathology, computer-assisted retinal vasculature analysis, optical coherence tomography angiography (OCTA), and NAM treatment. The main outcome measures included retinal vascular parameters in rats as assessed by AngioTool; retinal vasculature integrity in rats and humans as assessed by histopathology, antibody-staining, and ImageJ-based measurements; and retinal perfusion density (PD) and flux index in humans as assessed by OCTA. RESULTS: A number of vessel parameters were altered in ocular hypertension/glaucoma compared to healthy controls. NAM treatment improved the retinal vasculature in ocular hypertensive rats, with an increase in mean vessel area, percentage area covered by vessels, total vessel length, total junctions, and junction density as assessed by AngioTool (all P < 0.05); vessel wall integrity as assessed by VE-cadherin antibody staining was also improved (P < 0.01). In humans, as assessed by OCTA, increases in PD in the optic nerve head and macula complete image (0.7%, P = 0.04 and 1.0%, P = 0.002, respectively) in healthy controls, and an increase in the temporal quadrant of the macula (0.7%, P = 0.02) in glaucoma patients was seen after NAM treatment. CONCLUSIONS: NAM can prevent retinal vascular damage in an animal model of glaucoma. After NAM treatment, glaucoma patients and healthy controls demonstrated a small increase in retinal vessel parameters as assessed by OCTA.
引用
- Gustavsson ST, Enz TJ, Tribble JR, et al. Nicotinamide Prevents Retinal Vascular Dropout in a Rat Model of Ocular Hypertension and Supports Ocular Blood Supply in Glaucoma Patients. Invest Ophthalmol Vis Sci. 2023. PMID: 38010699. doi:10.1167/iovs.64.14.34
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。